ChAdOx1.85A+MVA85A

Phase of Development

Phase 2a

Vaccine Platform

Viral Vector

Candidate Overview

ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.

Sponsor / Lead Developer: University of Oxford

Clinical Trial Status: No Active Trials

Primary Indication: Prevention of TB disease

Other Indication(s): Prevention of Mtb infection or sustained infection and Prevention of TB recurrence

Target Population(s): Adolescents, Adults, Children, Infants, People cured of active TB, People living with HIV, People with Mtb infection, and People without Mtb infection

Target Route of Administration: Aerosol and Intramuscular

Clinical Trials

COMPLETED TRIALS
Registry Number	NCT03681860
Clinical Trial Phase	Phase 2a
Clinical Trial Sponsor	University of Oxford
Primary endpoint(s) for this clinical trial	Safety
Primary endpoint(s) for this clinical trial	Immunogenicity
Target population(s) for clinical trial	Adults
Target population(s) for clinical trial	Adolescents
Results/Publication	Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial (Lancet Infect. Dis., 2024)
_________________________
Registry Number	NCT01829490
Clinical Trial Phase	Phase 1
Clinical Trial Sponsor	University of Oxford
Primary endpoint(s) for this clinical trial	Safety
Target population(s) for clinical trial	Adults
Results/Publication	A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults (Vaccine, 2020)